Blog | Global Engage

UK +44 (0)1865 849841
Malaysia +603 2779 0098

What does international collaboration mean for you?

We asked three of our speakers what international collaboration means for them as leaders in their fields.

Read More
The Biosynthesis of Cannabinoids

We spoke to Jeremy Friedberg, CSO of LAVVAN, a company pioneering the biosynthesis of cannabinoids.

Read More
The Grass Has Never Been Greener For Engineering Plant Immunity And Resilience

The wide availability of sequencing technologies has been a rare step-change that has unlocked knowledge in a way nobody in the field could have imagined twenty years ago. Knowledge which could make a considerable contribution to food security in the face of changing climates.

Read More
How to beneficially modulate vaginal microbiota to optimise women’s health

Vaginal microbiota plays a crucial role in women’s health and successful reproduction. However, we are just on the verge of discovering the full potential and features of this unique microbial community within women.

Read More

Life Science
Agricultural Biotechnology
Technology

Submission-ready microbiome data for clinical trials

Posted 8th September 2023 by Ellie Egginton

Enabled by clonal-level microbiome profiling engraftment analysis, metabolomics and multi-omics analysis

The Microbiome & Probiotics R&D and Business Collaboration Forum recently hosted Marianne Koliana, VP of Business Development at Clinical Microbiomics. In the presentation she delved into crucial aspects of clinical trials, including regulatory compliance, engraftment analysis, and the pivotal role of multi-omics approaches, offering a comprehensive understanding of the evolving field.

Unravelling the Complexity of NAFLD: Insights from Professor Chris Byrne’s Presentation at the Global NASH Congress

Posted 8th June 2023 by Nicholas Noakes

The 6th Global NASH Congress in London witnessed an enlightening presentation by Professor Chris Byrne, a distinguished metabolic physician and endocrinologist. His comprehensive exploration of non-alcoholic fatty liver disease (NAFLD) unveiled its intricate nature as a multisystem disorder. This blog post aims to delve deeper into the key insights shared by Professor Byrne, elaborating on the relationship between NAFLD and type 2 diabetes, the significance of diagnosing NAFLD in patients living with diabetes, the potential benefits of PPAR gamma agonists, and the amplified risk of extrahepatic complications in NAFLD when people have type 2 diabetes.

Advancement in Therapeutics: Anti-Obesity Medications

Posted 11th May 2023 by Nicholas Noakes

Scott Harris, the Chief Medical Officer of Altimmune, gave a keynote address at the 6th Global NASH Congress where he discussed the development of drugs for both obesity and the treatment of NASH. He began by describing the statistics on obesity in the US and the lack of effective and safe therapies for the treatment of obesity in the past. He then highlighted the recent breakthroughs in incretin-based therapies, such as GLP-1, GLP-1/GIP, and GLP-1/glucagon dual agonists, which have shown promising results in clinical trials.

Digital pathology and service design

Posted 6th October 2022 by Nicholas Noakes

Digital health solutions in general have a poor track record of being sustained once they are implemented, often resulting in abandonment of the technology. Current digital pathology and artificial intelligence (AI) deployment strategies are generally too IT-focused – the technology being the focus, rather than the people and environment into which they are being deployed. Furthermore, a focus on technology alone will also hamper the effective integration of AI tools into the diagnostic workflow.

Discovering event sustainability in Brussels

Posted 28th April 2022 by Nicholas Noakes

“Our biggest challenge in this new century is to take an idea that seems abstract – sustainable development – and turn it into a reality ”
Kofi Annan

To try and turn that abstract idea into something more tangible, Global Engage has joined ISLA. This is a body that is working with the events industry to accelerate its transition to a sustainable future.

Switch to digital pathology bears fruit

Posted 11th March 2022 by Nicholas Noakes

Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.
Prof Alexi Baidoshvili

What is Net Zero and what does it mean for events?

Posted 10th February 2022 by Nicholas Noakes

As the world considers how it can mitigate climate change, Global Engage has committed to playing its part by reducing the impact of running events. But how to do it? I recently attended an onboarding course organised by ISLA and discovered that “Carbon Neutral” and “Net Zero” are not the same thing!

Digital Pathology: The Next Hurdles

Posted 31st January 2022 by Nicholas Noakes

A Market on the Rise
There has clearly been a surge in interest for digital pathology adoption over the last two years

Biobanking Biologics Biomaterials Bioprocessing Blockchain Cyber Security Digital Pathology Flow Cytometry Liquid Biopsies Medicinal Chemistry Microbiome Microfluidics NASH NGS PCR Pharma Informatics Precision Medicine Probiotics Synthetic Biology

Submission-ready microbiome data for clinical trials

Posted 8th September 2023 by Ellie Egginton

Enabled by clonal-level microbiome profiling engraftment analysis, metabolomics and multi-omics analysis

The Microbiome & Probiotics R&D and Business Collaboration Forum recently hosted Marianne Koliana, VP of Business Development at Clinical Microbiomics. In the presentation she delved into crucial aspects of clinical trials, including regulatory compliance, engraftment analysis, and the pivotal role of multi-omics approaches, offering a comprehensive understanding of the evolving field.

Unravelling the Complexity of NAFLD: Insights from Professor Chris Byrne’s Presentation at the Global NASH Congress

Posted 8th June 2023 by Nicholas Noakes

The 6th Global NASH Congress in London witnessed an enlightening presentation by Professor Chris Byrne, a distinguished metabolic physician and endocrinologist. His comprehensive exploration of non-alcoholic fatty liver disease (NAFLD) unveiled its intricate nature as a multisystem disorder. This blog post aims to delve deeper into the key insights shared by Professor Byrne, elaborating on the relationship between NAFLD and type 2 diabetes, the significance of diagnosing NAFLD in patients living with diabetes, the potential benefits of PPAR gamma agonists, and the amplified risk of extrahepatic complications in NAFLD when people have type 2 diabetes.

Advancement in Therapeutics: Anti-Obesity Medications

Posted 11th May 2023 by Nicholas Noakes

Scott Harris, the Chief Medical Officer of Altimmune, gave a keynote address at the 6th Global NASH Congress where he discussed the development of drugs for both obesity and the treatment of NASH. He began by describing the statistics on obesity in the US and the lack of effective and safe therapies for the treatment of obesity in the past. He then highlighted the recent breakthroughs in incretin-based therapies, such as GLP-1, GLP-1/GIP, and GLP-1/glucagon dual agonists, which have shown promising results in clinical trials.

Digital pathology and service design

Posted 6th October 2022 by Nicholas Noakes

Digital health solutions in general have a poor track record of being sustained once they are implemented, often resulting in abandonment of the technology. Current digital pathology and artificial intelligence (AI) deployment strategies are generally too IT-focused – the technology being the focus, rather than the people and environment into which they are being deployed. Furthermore, a focus on technology alone will also hamper the effective integration of AI tools into the diagnostic workflow.

Switch to digital pathology bears fruit

Posted 11th March 2022 by Nicholas Noakes

Fully digitising pathology operations has led to greater efficiency, cost savings, and quicker diagnosis for the Laboratory of Pathology East Netherlands (LabPON). The move, made six years ago, is showing measurable benefits and now, the institution is beginning to explore the potential of deep learning computational pathology algorithms, which might push the efficiency gains even further.
Prof Alexi Baidoshvili

Digital Pathology: The Next Hurdles

Posted 31st January 2022 by Nicholas Noakes

A Market on the Rise
There has clearly been a surge in interest for digital pathology adoption over the last two years

Highlights from the 9th Microbiome R&D and Business Collaboration Forum – Europe

Posted 10th January 2022 by Nicholas Noakes

It was clear that microbiome companies have been advancing their programs as rapidly as ever, despite the changes brought about by the global pandemic. Service providers—including drug manufacturing organizations—have been busy during the past year, as they continue actively helping diagnostics and therapeutics companies find solutions to advance their products.

Conversation with Dr Hamid Tizhoosh, Founder of KIMIA Lab and Leading Expert in the Development of Unsupervised AI for Tissue Pathology

Posted 30th September 2021 by Nicholas Noakes

“What we have to learn from day one when we design these AI applications, is that pathology has to come with us. We cannot just design a network as computer scientists and then go to the pathologists just when we need to validate it. The pathologist has to be with us from the start.“

Dr Hamid Tizhoosh

Biologicals Plant Genomics

Science Communication: challenges to ensure innovation can prove itself scientifically

Posted 6th July 2021 by Nicholas Noakes

John Entine is a science journalist who has been writing about sustainability issues in biotechnology for 30 years. He has written numerous books on both population genetic related issues and agricultural biotechnology. Presenting at the Plant Genomics & Gene Editing Congress, he gave his perspective on the communication challenges faced by scientists by looking specifically at gene drives and addressing misunderstandings about what the technology can do and active opposition to it by some environmental groups.

Why haven’t microbial products been more widely adopted by farmers?

Posted 14th October 2020 by Joshua Sewell

This is a question that drives me each day. Microbial products have been around for a long time; starting with rhizobium in legumes, dating back 125 years. Yet, in the United States, rhizobium inoculants have not been widely adopted by soybean farmers – some indicate less than 15% use overall in the United States. Why?

From Consortia to Recombinants: opportunities and challenges facing the next generation of microbials

Posted 24th August 2020 by Liv Sewell

In this blog post I will discuss two themes that I see driving the next generation of live microbe biologicals for agriculture. These are the rational design and delivery of pairs or consortia (which I will define as more than two microbes) and the commercialization of engineered strains.

What does international collaboration mean for you?

Posted 27th May 2020 by Liv Sewell

The present COVID-19 crisis has demonstrated the vital need for knowledge sharing across the global science community. We asked three of our speakers what international collaboration means for them as leaders in their fields.

The Biosynthesis of Cannabinoids

Posted 6th May 2020 by Joshua Sewell

We recently spoke to Jeremy Friedberg, CSO of LAVVAN, a company pioneering the biosynthesis of cannabinoids. The conversation was recorded as a podcast, which can be found here.

The grass has never been greener for engineering plant immunity and resilience

Posted 18th March 2020 by Liv Sewell

Scientific research is always working at the frontiers of knowledge, but plant genomics technologies have had a dramatic impact on plant science even by our standards. The wide availability of sequencing technologies has been a rare step-change that has unlocked knowledge in a way nobody in the field could have imagined twenty years ago. Knowledge which could make a considerable contribution to food security in the face of changing climates.

New Breeding Techniques: cloning major resistance genes in cereals

Posted 13th March 2020 by Liv Sewell

Advances in breeding techniques for cereal crops will be a focus at the 8^th Plant Genomics and Gene Editing Congress: USA. We asked Burleigh Dodds, an agricultural science publisher, to share an extract from one of their recent publications, ‘Advances in breeding techniques for cereal crops’.

Plant biotech in Europe: Present and future

Posted 4th March 2020 by Liv Sewell

Marcel Kuntz is a panellist for the panel discussion on the regulatory landscape for plant biotechnology at the 8^th Plant Genomics & Gene Editing Congress: Europe. Here he provides us with some background for the discussion.

What is Net Zero and what does it mean for events?

Posted 10th February 2022 by Nicholas Noakes

As the world considers how it can mitigate climate change, Global Engage has committed to playing its part by reducing the impact of running events. But how to do it? I recently attended an onboarding course organised by ISLA and discovered that “Carbon Neutral” and “Net Zero” are not the same thing!

Multiplex and high fidelity: the potential of qPCR

Posted 28th August 2020 by Joshua Sewell

Ahead of the qPCR & Digital PCR Congress, we sat down with David Zhang to talk about his work with PCR as a diagnostic platform.

Examining Blockchain Systems & Designing Smart Contracts

Posted 13th August 2018 by Jane Williams

The blockchain has the potential to enable the collaboration between patients, researchers, and care providers to provide individualised care for patients, but how can this technology be harnessed in a practical way?

This was one of the key questions that was asked at the Blockchain in Healthcare Congress and we had the pleasure of welcoming an array of expert speakers from pharma, academia, and industry to provide the answer.

The role of extrinsic motivation in sports and physical activity

Posted 20th June 2018 by Jane Williams

Motivation is one of the most significant psychological concepts in many areas of life – from work and education to achieving personal goals. In sports and physical activity, motivation plays an especially important part due to the fact that, to millions of people worldwide, staying fit and active is not an obligation or a professional prerequisite, but rather a personal goal. Blockchain technology, together with elements of gamification, may actually help people achieve this goal.

Conciliating Blockchain and GDPR

Posted 8th June 2018 by Jane Williams

Aurélie Bayle is a Data Protection Officer at be-ys: a role she considers to be at the heart of the new legal framework for any company.

Before GDPR came into effect on 25^th May 2018, she was working towards global compliance, which involved completing all the steps given by the Article 29 Data Protection Working Party, an advisory board made up of a representative from the data authority of each EU Member State, the European Data Protection Supervisor, and the European Commission. Her duties have included auditing the structures and processes, preparing the data protection impact assessments, checking the compliance of processing activities, analysing the risks of the processing in the medical area, preparing new processes and policies about data protection, and asking data processors about their own compliance.

When Blockchain Meets the Right to be Forgotten: Technology Versus Law

Posted 2nd May 2018 by Jane Williams

Over the past few years, the popularity of the blockchain and cryptocurrencies has increased and has reached important notoriety, not only in scientiﬁc and IT journals, but also in the media. Although there are many kinds of cryptocurrencies in circulation nowadays, the most popular is Bitcoin.

Supporting Blockchain Startups: An Open Letter from Katherine Merton

Posted 27th April 2018 by Jane Williams

Dear colleagues,

The blockchain technology market is expected to grow to 2.3 billion US dollars by 2021, from 339.5 million US dollars in 2017. [1] With an annual growth rate of 61.5%, it is one of the fastest growing technologies in the healthcare industry.

The Big List of Microfluidics Companies & Investors

Posted 25th April 2018 by Jane Williams

The microfluidic-based devices market has been growing since 2014 due to the increasing point of care testing demand and the miniaturisation of microfluidic chips.

Archive